Opiant Pharmaceuticals (NASDAQ:OPNT) issued its earnings results on Monday. The technology company reported ($2.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($1.58), Bloomberg Earnings reports. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%.

Opiant Pharmaceuticals (NASDAQ OPNT) traded up $0.80 during trading on Tuesday, reaching $31.36. The company’s stock had a trading volume of 31,300 shares, compared to its average volume of 35,379. Opiant Pharmaceuticals has a 52 week low of $5.00 and a 52 week high of $51.90. The stock has a market capitalization of $62.28, a PE ratio of 10.57 and a beta of -2.33.

OPNT has been the subject of several research reports. ValuEngine upgraded Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. TheStreet upgraded Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Monday, October 16th.

WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/05/opiant-pharmaceuticals-opnt-posts-quarterly-earnings-results.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Earnings History for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Stock Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.